Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.

Zhou, Lin; Ai, Ding-Lun; Fu, Junliang; Peng, Xiaoming; Linzhi, Zhang; Zhao, Yun; Wang, Jingyan; Yu, Qiang; Liu, Chunzi; Ma, Wei; Wang, Huaming

doi:10.1200/jco.2014.32.15_suppl.e15120

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The group treated with Livin peptide‐loaded DC‐CIK cells showed a longer mPFS by 1.9 months and a higher ORR by 18%, significantly. The tyrosine kinase inhibitors sunitinib and sorafenib were also applied in two CIK cell‐based studies (Mai et al, 2018; Z. Zhou, Qin, Weng, & Ni, 2019). In the study targeting advanced hepatocellular carcinoma, the combination of sorafenib and DC‐CIK cells decreased the alanine transaminase and total bilirubin levels and improved the clinical benefit rate (88.6% vs. 41.9%) and mOS (18.6 vs. 13.8) statistically when compared with the control group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Zhang

Schmidt‐Wolf

2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Cytokine‐induced killer (CIK) cells represent an exceptional T‐cell population uniting a T cell and natural killer cell‐like phenotype in their terminally differentiated CD3+CD56+ subset, which features non‐MHC‐restricted tumor‐killing activity. CIK cells have provided encouraging results in initial clinical studies and revealed synergistic antitumor effects when combined with standard therapeutic procedures. We established the international registry on CIK cells (IRCC) to collect and evaluate clinical trials for the treatment of cancer patients in 2010. Moreover, our registry set new standards on the reporting of results from clinical trials using CIK cells. In the present update, a total of 106 clinical trials including 10,225 patients were enrolled in IRCC, of which 4,889 patients in over 30 distinct tumor entities were treated with CIK cells alone or in combination with conventional or novel therapies. Significantly improved median progression‐free survival and overall survival were shown in 27 trials, and 9 trials reported a significantly increased 5‐year survival rate. Mild adverse effects and graft‐versus‐host diseases were also observed in the studies. Recently, more efforts have been put into the improvement of antitumoral efficacy by CIK cells including the administration of immune checkpoint inhibitors and modification with chimeric antigen receptorc. The minimal toxicity and multiple improvements on their tumor‐killing activity both make CIK cells a favorable therapeutic tool in the clinical practice of cancer immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The tyrosine kinase inhibitors sunitinib and sorafenib were also applied in two CIK cell-based studies (Mai et al, 2018;Z. Zhou, Qin, Weng, & Ni, 2019).…”

Section: Clinical Outcome Therapeutic Regime and Quality Of Lifementioning

confidence: 99%

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Zhang

Schmidt‐Wolf

2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…As far as we are aware, this is the first report of DC-CIK therapy for CLL and peritoneal cancer, respectively. The use of DC-CIK as an adjunct to standard cancer treatments has piqued the interest of oncologists due to convincing results reported by preclinical and clinical trials in several different cancer types (9,(11)(12)(13)(14). Research investigating a combination of DC-CIK immunotherapy and chemotherapy in different cancer types has revealed significant variations in cell dosage.…”

Section: Discussionmentioning

confidence: 99%

Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

Mehling,

Wu,

O’Gorman

et al. 2023

Front. Med.

View full text Add to dashboard Cite

This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively. Participants had received conventional chemotherapy treatment for their specific cancers, and in addition, 1–2 treatments of DC-CIK therapy were administered to subjects over the course of 1 year. Subject A received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and a repeat dosage 6 months later. Subject B received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and received further chemotherapy after approximately 1 year. No treatment-related adverse events were reported, and both patients experienced favorable outcomes from the treatment, including enhanced treatment response, increased chemotherapy tolerance, and prolonged survival in comparison to typical 5-year survival rates.

show abstract

Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.

Cited by 2 publications

References 0 publications

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

Contact Info

Product

Resources

About